



28 March 2022

Creso Pharma's wholly-owned psychedelics subsidiary, Halucenex Life Sciences Inc. completes important milestones ahead of first psilocybe mushroom harvest

Highlights:

- **Upgrades to grow room completed allowing Halucenex to commence maiden mushroom cultivation program**
- **Company has recently completed installation of food-grade washable wall and ceiling panels and heat and humidity control systems for growing psilocybe mushrooms**
- **Steps toward cultivation are now underway with first harvest anticipated in the coming months**
- **Growing botanical psilocybe mushrooms will allow Halucenex more cost-effective R&D**
- **High Performance Liquid Chromatography (HPLC) System successfully commissioned to test Active Pharmaceutical Ingredients in synthetic and botanical psilocybe mushrooms**
- **HPLC methods are used in pharmaceutical manufacturing, R&D and for medical purposes – system expected to provide extensive insight ahead of product development initiatives**
- **Method development protocols for psilocybin, psilocin potency and purity testing being currently established in collaboration with R&D partners**

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to advise that wholly-owned, Canadian based psychedelics company, Halucenex Life Sciences Inc. ("Halucenex") has completed several milestones that will allow the Company to progress its first psilocybin mushroom harvest and other product development initiatives.

Upgrades to state-of-the-art grow room:

Halucenex has completed a series of renovations to its grow rooms at its medical facility in Nova Scotia. The recent upgrades will lay the foundation for the Company's maiden harvest of inoculated psilocybe mushrooms.

The Company has completed the installation of food-grade washable wall and ceiling panels, as well as commissioned heat and humidity control systems for growing psilocybe mushrooms. The facility upgrade follows extensive internal consultations and discussions with partners to ensure optimal growing conditions.

Halucenex will now progress steps towards cultivation and anticipates its first harvest to complete within the next three months. Harvested psilocybe mushrooms will then be used for R&D and product development initiatives.

Successfully commissioning of High Performance Liquid Chromatography (HPLC) System:

Halucenex has also recently installed a high performance liquid chromatography system at its medical facility in Nova Scotia, which will be utilised to test the active pharmaceutical ingredients (API) in both synthetic and botanical psilocybe mushrooms.



HPLC is an analytical chemistry technique used to separate, identify and quantify each component in a mixture. The method is commonly used for pharmaceutical manufacturing, R&D and for medical purposes.

Halucenex will use the new HPLC system to gain further insight into the level of APIs in synthetic and botanical psilocybe mushrooms cultivated at its facility. This is an important development, as it will provide Halucenex with additional data which can be used for initial product development initiatives.

Method development for psilocybin and psilocin potency and purity testing are currently being established in collaboration with the Company's R&D partners.

Commentary:

Managing Director and CEO Mr William Lay said: *"Halucenex has continued to make very strong, value accretive progress over the course of 2022.*

"The successful commissioning of the HPLC system will allow the group to gain a detailed understanding of botanical and synthetic psilocybin content and purity. This is imperative as we move towards product development and other research initiatives.

"The recent renovations to the Company's grow room are an important milestone ahead of our first planned harvest. The initiative has laid a strong foundation to commence cultivation, which will provide cost effective biomass for R&D purposes.

"The Board and management look forward to providing additional updates to shareholders, once ethics approval for the planned clinical trial has been secured and patient recruitment initiatives are underway."

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of the Board of Directors of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

Creso Pharma Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which



enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Creso Pharma offices:

Australia

Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Switzerland

Allmendstrasse 11, 6310 Steinhausen, Schweiz

Canada

59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.